PB 77 of 2024

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024
(No. 7)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 30 July 2024

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015). 2

1 Name

(1)           This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 7).

(2)           This instrument may also be cited as PB 77 of 2024.

2 Commencement

(1)           Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)           Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

[1]           Schedule 1, after entry for Adalimumab in the form Injection 20 mg in 0.2 mL pre-filled syringe [Maximum quantity or number of units: 2; Maximum number of repeats: 5]

insert:

[2]           Schedule 1, after entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled pen [Maximum quantity or number of units: 2; Maximum number of repeats: 5]

insert:

[3]           Schedule 1, after entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen [Maximum quantity or number of units: 2; Maximum number of repeats: 5]

insert:

[4]           Schedule 1, after entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe [Maximum quantity or number of units: 2; Maximum number of repeats: 5]

insert:

[5]           Schedule 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium)

omit:

[6]           Schedule 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium)

omit:

[7]           Schedule 1, entry for Fenofibrate in the form Tablet 48 mg

omit:

[8]           Schedule 1, entry for Fenofibrate in the form Tablet 145 mg

omit:

[9]           Schedule 1, entry for Fluvastatin

omit:

[10]       Schedule 1, entry for Gemfibrozil

omit:

[11]       Schedule 1, omit entry for Oxprenolol

[12]       Schedule 1, after entry for Selegiline

insert:

[13]       Schedule 1, entry for Simvastatin in each of the forms: Tablet 5 mg; Tablet 10 mg; Tablet 20 mg; Tablet 40 mg; and Tablet 80 mg

omit:

[14]       Schedule 1, entry for Sulfasalazine in each of the forms: Tablet 500 mg; and Tablet 500 mg (enteric coated)

omit:

[15]       Schedule 1, entry for Teriparatide

omit: